Ionis Pharmaceuticals IONS Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's accrued expenses?
- Ionis Pharmaceuticals (IONS) reported accrued expenses of $36.05M in Q1 2026.
- How has Ionis Pharmaceuticals's accrued expenses changed year-over-year?
- Ionis Pharmaceuticals's accrued expenses increased by 35.7% year-over-year, from $26.58M to $36.05M.
- What is the long-term trend for Ionis Pharmaceuticals's accrued expenses?
- Over 5 years (2020 to 2025), Ionis Pharmaceuticals's accrued expenses has grown at a 12.1% compound annual growth rate (CAGR), from $65.73M to $116.24M.
- What does accrued expenses mean?
- Expenses the company has incurred but has not yet received a bill for or paid.
- How do you interpret accrued expenses?
- Fluctuations often track with operational activity levels and the timing of periodic payments like payroll or research milestones.
- How does accrued expenses compare across companies?
- Common across all companies; reflects the accrual basis of accounting.